1. BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

2. Why Large-Outcome RCTs?

3. Recent CV Outcome Trials with DPP-4 Inhibitors and GLP-1 Receptor Agonists

4. SAVOR-TIMI 53: Primary Endpoint

5. SAVOR-TIMI 53: Hospitalization for HF

6. SAVOR-TIMI 53: Patients at Risk for HF

7. EXAMINE: Primary Endpoint

8. EXAMINE: Hospitalization for HF

9. TECOS: Effect of Sitagliptin vs Placebo on CV Outcomes in T2DM

10. TECOS: Hospitalization for HF

11. TECOS: HF and Mortality Outcomes in Patients With Prior HF

12. TECOS: Non-CV Outcomes

13. ELIXA: CV Outcomes by Treatment Group

14. ELIXA: CV Death + HF Hospitalization by History of HF

15. ELIXA: Symptomatic Hypoglycemia: Time to First Event

16. ELIXA Safety Summary: AEs by Treatment

17. ELIXA Safety Summary: Other

18. New CV Outcome Trial with an SGLT2 Inhibitor: EMPA-REG OUTCOME

19. EMPA-REG OUTCOME: Trial Design

20. EMPA-REG OUTCOME: 3-Point MACE*

21. 3-point MACE: Subgroup Analysis

22. EMPA-REG OUTCOME: CV Death

23. CV Death: Subgroup Analyses

24. EMPA-REG OUTCOME: CV Death, MI, and Stroke

25. EMPA-REG OUTCOME: All-cause Mortality

26. EMPA-REG OUTCOME: Hospitalizations for HF

27. EMPA-REG OUTCOME: AEs*

28. EMPA-REG OUTCOME Study: Summary

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)